3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
7
Active not recruiting
2
Unknown
1
Terminated
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
3
Breast
3
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Conditions
Urinary Bladder Neoplasms
1
Peripheral Nervous System Diseases
1
Interventions
Gemcitabine
13
Radiotherapy
12
Androgen Antagonists
12
Specimen Handling
11
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Nivolumab
8
toripalimab
7
darolutamide
7
Drug Therapy
7
Radiosurgery
6
Docetaxel
6
Cystectomy
6
enzalutamide
5
apalutamide
5
Mitomycin
5
Cisplatin
5
Axitinib
5
Abiraterone Acetate
5
disitamab vedotin
4
cabozantinib
4
abiraterone
4
Pluvicto
4
Cyclophosphamide
4
tislelizumab
3
lenvatinib
3
fludarabine
3
cemiplimab
3
Sunitinib
3
Standard of Care
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Acupuncture Therapy
×
Genitourinary
×
Clear all
NCT07548476
2026-05-04
ACE
Dana-Farber Cancer Institute
Phase NA
Not yet recruiting
50 enrolled